COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES IN CHINA

被引：1
|
作者：
Gao, L. [1 ]
Li, S. C. [1 ]
机构：
[1] Univ Newcastle, Callaghan, NSW 2308, Australia
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.358
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A663 / A663
页数：1
相关论文
共 50 条
  • [1] COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN TYPE 2 DIABETES PATIENTS IN CHINA
    Gao, Lan
    Zhao, Fei-Li
    Li, Shu-Chuen
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2012, 28 (04) : 436 - 444
  • [2] Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
    Davies, M. J.
    Chubb, B. D.
    Smith, I. C.
    Valentine, W. J.
    DIABETIC MEDICINE, 2012, 29 (03) : 313 - 320
  • [3] Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin
    Hermansen, Kjeld
    Kolotkin, Ronette L.
    Hammer, Mette
    Zdravkovic, Milan
    Matthews, David
    PRIMARY CARE DIABETES, 2010, 4 (02) : 113 - 117
  • [4] Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
    Kousoulakou, Hara
    Hatzikou, Magdalini
    Baroutsou, Varvara
    Yfantopoulos, John
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017, 15
  • [5] Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
    Hara Kousoulakou
    Magdalini Hatzikou
    Varvara Baroutsou
    John Yfantopoulos
    Cost Effectiveness and Resource Allocation, 15
  • [6] COST-UTILITY ANALYSIS OF SAXAGLIPTIN AS AN ADD-ON THERAPY TO METFORMIN IN TYPE 2 DIABETES PATIENTS FROM THE BRAZILIAN PRIVATE HEALTH SYSTEM
    Eliaschewitz, F. G.
    Asano, E.
    Nita, M. E.
    Rached, R.
    Donato, B. M.
    VALUE IN HEALTH, 2010, 13 (07) : A295 - A295
  • [7] Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus
    Hu, Shanshan
    Deng, Xun
    Ma, Yanjiao
    Li, Zhilei
    Wang, Yuhang
    Wang, Yong
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2021, 19 (01) : 69 - 79
  • [8] Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus
    Shanshan Hu
    Xun Deng
    Yanjiao Ma
    Zhilei Li
    Yuhang Wang
    Yong Wang
    Applied Health Economics and Health Policy, 2021, 19 : 69 - 79
  • [9] Empaglilozin compared with glimepiride as add-on to metformin for 2 years in patients with type 2 diabetes
    Ridderstrale, M.
    Andersen, K. R.
    Zeller, C.
    Kim, G.
    Woerle, H. J.
    Broedl, U. C.
    DIABETOLOGIA, 2014, 57 : S7 - S8
  • [10] Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes
    Mueller-Wieland, Dirk
    Kellerer, Monika
    Cypryk, Katarzyna
    Skripova, Dasa
    Rohwedder, Katja
    Johnsson, Eva
    Garcia-Sanchez, Ricardo
    Kurlyandskaya, Raisa
    Sjostrom, C. David
    Jacob, Stephan
    Seufert, Jochen
    Dronamraju, Nalina
    Csomos, Katalin
    DIABETES OBESITY & METABOLISM, 2018, 20 (11): : 2598 - 2607
12345